Impact News +++ Wave Life Sciences reports durable AAT protein production with repeat doses of WVE-006; stock down 21% (SeekingAlpha) +++ WAVE LIFE SCIENCES Aktie -15,63%

TALPHERA Aktie

>TALPHERA Aktienkurs

0.4635 EUR (Tradegate)

Ask: 0.4725 EUR / 2200 Stück

Bid: 0.4545 EUR / 2300 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TALPHERA Aktie über LYNX handeln

Intraday

1 Jahr

>TALPHERA Performance

1 Woche: -8,0%

1 Monat: +29,1%

3 Monate: +9,5%

6 Monate: -16,9%

1 Jahr: -52,0%

laufendes Jahr: -11,2%

>TALPHERA Aktie

Name:

TALPHERA INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00444T2096 / A3DWPN

Symbol/ Ticker:

R5XA (Frankfurt) / TLPH (NASDAQ)

Kürzel:

FRA:R5XA, ETR:R5XA, R5XA:GR, NASDAQ:TLPH

Index:

Webseite:

https://talphera.com/

Profil:

Talphera Inc. is a dynamic entity in the competiti..
>Volltext..

Marktkapitalisierung:

9.54 Mio. EUR

Unternehmenswert:

9.3 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

-11.48 Mio. EUR

Nettogewinn:

-9.72 Mio. EUR

Gewinn je Aktie:

-0.34 EUR

Schulden:

5.59 Mio. EUR

Liquide Mittel:

5.84 Mio. EUR

Operativer Cashflow:

-9.98 Mio. EUR

Bargeldquote:

2.58

Umsatzwachstum:

-93.83%

Gewinnwachstum:

24.72%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TALPHERA, ACELRX

Letzte Datenerhebung:

03.09.25

>TALPHERA Kennzahlen

Aktien/ Unternehmen:

Aktien: 20.52 Mio. St.

Frei handelbar: 96%

Leerverk. Aktien: 0.13%

Rückkaufquote: -39.41%

Mitarbeiter: 13

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 501.75%

Bewertung:

KGV: -

KGV lG: -

KUV: 699.28

KBV: 1.68

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -42140.74%

Operative Marge: -49459.26%

Managementeffizenz:

Gesamtkaprendite: -55%

Eigenkaprendite: -117.56%

>TALPHERA Peer Group

Es sind 601 Aktien bekannt.

>TALPHERA Chart & Kurs - NASDAQ

>TALPHERA News

25.08.25 - 14:33	Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial (PR Newswire)
	The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc.......

15.08.25 - 03:18	Talphera outlines accelerated NEPHRO enrollment and lowers 2025 cash operating expense guidance amid protocol shift (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 00:12	Talphera Cuts Expenses 14 Percent (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 23:48	Talphera Cuts Costs and Speeds Trial (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 23:48	Talphera TLPH Q2 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:09	Talphera GAAP EPS of -$0.10 beats by $0.03 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:06	Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday,......

07.08.25 - 22:39	Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025 (PR Newswire)
	SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second......

15.05.25 - 03:06	Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:12	Talphera GAAP EPS of -$0.10 beats by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:09	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional......

07.05.25 - 22:06	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire)
	SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first......

06.05.25 - 19:30	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
	Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

04.04.25 - 19:45	Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
	Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

04.04.25 - 02:01	Insiderhandel: CHIEF EXECUTIVE OFFICER kauft Aktien von Talphera im Wert von 125000 USD (Insiderkauf)
	Angotti, Vincent J. - Vorstand - Tag der Transaktion: 2025-04-02...

01.04.25 - 00:42	Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 22:09	AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 22:06	Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
	The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the......

30.03.25 - 23:39	AcelRx Pharmaceuticals Q4 2024 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.25 - 21:39	Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 (PR Newswire)
	SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine Pfarrgemeinde ist ein Verein von Einzelpersonen, bei denen der Hirte am einsamsten ist. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram